Nightfood Holdings Inc. (OTCQB: NGTF) announced that its subsidiary, TechForce Robotics, has successfully completed Phase 1 objectives under its joint development agreement with Oncotelic Therapeutics (OTCQB: OTLC), highlighted by the initial deployment of LIM-E, an autonomous laboratory support robot. The deployment marks TechForce’s first expansion into pharmaceutical and laboratory automation and validates the adaptability of its AI-enhanced robotics platform beyond hospitality and service-industry applications into life sciences and pharmaceutical environments.
TechForce said the deployment completed the initial operational goals established under the companies’ April 2026 collaboration agreement and will provide operational data and workflow insights to support future automation initiatives. The companies plan to continue evaluating opportunities in laboratory logistics, manufacturing support, AI-enhanced workflows and other automation applications, while Nightfood views healthcare, life sciences and pharmaceutical manufacturing as significant long-term growth markets for its Robotics-as-a-Service platform.
This milestone is significant for both companies and the broader automation industry. For Nightfood Holdings, the successful deployment of LIM-E demonstrates the versatility of its robotics platform and opens a new revenue stream in the high-value pharmaceutical sector. The company’s Robotics-as-a-Service (RaaS) model, which allows clients to deploy automation without large upfront capital expenditures, could accelerate adoption in laboratories and manufacturing facilities that are increasingly seeking to improve efficiency and consistency.
For Oncotelic Therapeutics, a clinical-stage biopharmaceutical company focused on oncology and immunotherapy products, the collaboration with TechForce could enhance its operational capabilities in drug development and manufacturing. By integrating autonomous robots into laboratory workflows, Oncotelic may reduce human error, increase throughput, and free up skilled scientists for higher-value tasks.
The implications for the pharmaceutical industry are substantial. Laboratory automation is a growing trend, driven by the need for faster drug discovery, stricter quality control, and cost reduction. TechForce’s entry into this space with a proven AI-enhanced platform could accelerate the adoption of robotics in labs worldwide. Moreover, the collaboration between a robotics company and a biopharmaceutical firm exemplifies the cross-industry partnerships that are becoming essential for innovation.
Investors and industry observers will be watching closely as TechForce and Oncotelic move to Phase 2 of their agreement. The companies have not disclosed specific financial terms or timelines for future phases, but the initial success suggests strong potential for expanded deployment. Nightfood Holdings, which also operates in the hospitality and foodservice sectors, is positioning itself as a diversified automation provider with a growing footprint in life sciences.
For more information, visit Nightfood Holdings and TechForce Robotics.
